Alphamab Oncology Balance Sheet Health
Financial Health criteria checks 5/6
Alphamab Oncology has a total shareholder equity of CN¥1.6B and total debt of CN¥320.0M, which brings its debt-to-equity ratio to 19.6%. Its total assets and total liabilities are CN¥2.1B and CN¥513.3M respectively.
Key information
19.6%
Debt to equity ratio
CN¥320.00m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.46b |
| Equity | CN¥1.63b |
| Total liabilities | CN¥513.25m |
| Total assets | CN¥2.14b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9966's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥345.4M).
Long Term Liabilities: 9966's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥167.9M).
Debt to Equity History and Analysis
Debt Level: 9966 has more cash than its total debt.
Reducing Debt: 9966 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9966 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 9966 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.